Araris Biotech Publishes Foundational Science Behind its Novel Antibody-Drug Conjugate Platform in ChemBioChem
November 12, 2024 08:00 ET
|
Araris Biotech
First characterization of its novel conjugation technology for creating stable, well-defined ADCs with linkers that enable payload attachment to native, unmodified antibodies at a universally...
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC
November 07, 2024 08:30 ET
|
Vaccinex, Inc.
Partnerships will employ Vaccinex’s ActivMAb® tech. Successful antibody discovery campaigns for cancer immunotherapy to be presented at SITC Nov 9, 2024.
MacroGenics to Participate in Upcoming Investor Conferences
November 06, 2024 16:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Nov. 06, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal...
MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results
November 05, 2024 16:01 ET
|
MacroGenics, Inc.
Strengthened financial position resulting from recently announced MARGENZA® transaction and previously announced receipt of milestone payment from Incyte related to advancement of ZYNYZ®ADAM9-directed...
MacroGenics Announces Leadership Transition
October 30, 2024 07:30 ET
|
MacroGenics, Inc.
Scott Koenig, M.D., Ph.D., to step down as President and CEOBoard to initiate search process to identify new CEO ROCKVILLE, MD, Oct. 30, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:...
MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call
October 29, 2024 16:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Oct. 29, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based...
EpimAb Biotherapeutics Announces Upcoming Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
October 10, 2024 21:00 ET
|
Shanghai EpimAb Biotherapeutics Co., Ltd.
SHANGHAI, Oct. 11, 2024 (GLOBE NEWSWIRE) -- EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies and T-cell engagers, is pleased to...
Distinguished Oncologist, Professor Daniel Von Hoff joins the Scientific/Clinical Advisory Board of EnGeneIC Cancer Therapeutics
October 01, 2024 08:00 ET
|
EnGeneIC
EnGeneIC appoints Dr. Daniel Van Hoff to its Scientific Advisory Board to advise on clinical oncology programs, including upcoming PDAC trial.
Araris Biotech AG Expands its IP Portfolio with the Acquisition of Innate Pharma’s Portfolio of Transglutaminase Patents for the Generation of Antibody-Drug Conjugates (ADCs)
September 24, 2024 08:00 ET
|
Araris Biotech
Araris Biotech AG Expands its IP Portfolio with the Acquisition of Innate Pharma’s Portfolio of Transglutaminase Patents for the Generation of Antibody-Drug Conjugates (ADCs) AU ZH, SWITZERLAND,...
MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024
September 15, 2024 03:00 ET
|
MacroGenics, Inc.
Encouraging antitumor activity demonstrated with vobra duo as measured by 6-month landmark rPFS rate and ORRPatients remained on vobra duo through a median of 6 doses (ranging up to 12), representing...